




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 47/48		A2	(11) International Publication Number: WO 98/00171
			(43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/IB97/01093		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 June 1997 (30.06.97)			
(30) Priority Data: 08/674,315 1 July 1996 (01.07.96) US			
(71) Applicant: REDCELL CANADA INC. [CA/CA]; Suite 810, 1801 Boulevard de Maisonneuve Ouest, Montreal, Quebec H3H 1J9 (CA).			
(72) Inventors: KRANTZ, Alexander; Apartment D24, 350 Sharon Park Drive, Menlo Park, CA 94025 (US). EZRIN, Alan, M.; 110 Quintas Lane, Moraga, CA 94556 (US). SONG, Yonghong; Apartment K309, 1125 Bakclutha Drive, Foster City, CA 94404 (US).		Published Without international search report and to be republished upon receipt of that report.	
(74) Agent: COTE, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3 (CA).			

(54) Title: CONJUGATES OF THROMBIN INHIBITORS AND ENDOGENES CARRIERS



(57) Abstract

Novel compounds comprising chemically reactive intermediates which can react with available reactive functionalities on blood components to form covalent linkages, where the resulting covalently-bound conjugates are found to have thrombin inhibition activity are provided. Specifically, the thrombin inhibitor compounds of the present invention are derivatives of the known thrombin inhibitor argatroban, which can be covalently linked to chemically reactive functionalities on various blood components. The conjugated thrombin inhibitors thereby have extended lifetimes in the blood stream, as compared to the unconjugated parent drug, and are, therefore, capable of maintaining thrombin inhibitory activity for extended periods of time as compared to the unconjugated parent drug. Also provided herein are methods for inhibiting thrombin activity *in vivo* comprising administering to the bloodstream of a mammalian host the novel compounds of the present invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONJUGATES OF THROMBIN INHIBITORS AND ENDOGENES CARRIERS

INTRODUCTIONTechnical Field

The field of this invention is the extended lifetime of physiologically active agents in a mammalian host, more specifically, the extended lifetime of inhibitors of
5 thrombin activity in a mammalian host.

Background

In the past, there have been many attempts to obtain new and improved agents for the treatment of thrombosis. The N²-(p-tolysulfonyl)-L-arginine esters are one type of agent which can be used and these have been found to be effective in
10 dissolving blood clots (see U.S. Patent No. 3,622,615, issued November 23, 1971). Another family of compounds which have been found to be particularly useful as highly specific inhibitors of thrombin for the control of thrombosis is the N²-dansyl-L-arginine esters or amides (U.S. Patent No. 3,978,045) and many N²-arylsulfonyl-L-argininamides. Moreover, another compound which has proven to be particularly
15 useful for the treatment of thrombosis in mammals is 1-[5-[Aminoiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-

quinoliny]sulfonyl]-amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, a compound which is commonly known as argatroban.

Although the above described compounds have proven useful for the treatment of disorders associated with abnormal thrombosis via inhibition of

5 thrombin activity *in vivo*, their therapeutic utility is somewhat limited due to the fact that many of these compounds are quickly degraded and/or removed from the host's vascular system after administration. As such, for continuous thrombin inhibitory activity over extended periods of time, the above described thrombin inhibitors must be administered as a large bolus given at periodic time intervals or by providing

10 depots comprising the drug. Unfortunately, however, administration of large boluses at periodic time intervals often results in subtherapeutic doses of the drug for extended periods of time followed by doses which may greatly exceed the desired therapeutic level. The latter may often involve serious adverse side effects. Moreover, although various pumps and biodegradable and non-biodegradable

15 capsules have been devised for the delivery of drug over an extended period of time, these devices may have a variety of shortcomings in their profile of drug delivery, for example, often resulting in an inflammatory response and/or being subject to interference in their release of active drug.

There is, therefore, an interest in providing improved therapies associated

20 with thrombin inhibition.

SUMMARY OF THE INVENTION

Novel compounds are provided comprising chemically reactive intermediates which can react with available reactive functionalities on blood components to form covalent linkages, where the resulting covalently-bound conjugates are found to have

25 thrombin inhibition activity. Specifically, the compounds of the present invention are chemically reactive derivatives of the known thrombin inhibitor 1-[5-[Aminoiminomethyl]amino]-1-oxo-2-[(1,2,3,4-tetrahydro-3-methyl-8-quinoliny]sulfonyl]-amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, a compound also known as argatroban. The derivatized argatroban molecules of the

present invention comprise an active thrombin inhibitor portion and become covalently linked through a chemically reactive group to reactive functionalities on various blood components. The conjugated thrombin inhibitor molecules thereby have extended lifetimes in the bloodstream, as compared to the unconjugated parent drug, and are, therefore, capable of maintaining thrombin inhibitory activity for extended periods of time as compared to the unconjugated parent drug.

Also provided herein are compositions comprising the derivatized thrombin inhibitor molecules described above combined with pharmaceutically acceptable carriers and methods for inhibiting thrombin activity *in vivo* comprising administering to the bloodstream of a mammalian host the novel compounds of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic depiction of the steps involved in the synthesis of various derivatized thrombin inhibitor molecules of the present invention.

Figure 2 is a graph showing the results obtained in sandwich ELISA assays with human serum albumin (HSA) alone ("●"), HSA treated with prequenched hydroxylamine treated argatroban-C6 NHS ester ("Δ"), HSA treated with prequenched argatroban-C12 NHS ester ("*"), HSA reacted with argatroban-C6 NHS ester ("◆") or HSA reacted with argatroban-C12 NHS ester ("X"). Results are presented as the absorbance at 490 nm ("OD 490") versus HSA concentration in nanograms per milliliter ("ng/ml").

Figure 3 is a graph showing the results obtained in sandwich ELISA assays with rabbit serum albumin (RSA) alone ("Δ"), RSA reacted with prequenched argatroban-C6 NHS ester ("■") or RSA reacted with argatroban-C6 NHS ester ("◆"). Results are presented as the absorbance at 490 nm ("OD 490") versus RSA concentration in nanograms per milliliter ("ng/ml").

Figure 4 is a graph showing the results obtained in sandwich ELISA assays with human glycoprotein A (hGPA) alone ("Δ"), hGPA treated with prequenched argatroban-C6 NHS ester ("■") or hGPA treated with argatroban-C6 NHS ester

("♦"). Results are presented as the absorbance at 490 nm ("OD 490") versus hGPA concentration in nanograms per milliliter ("ng/ml").

Figure 5 is a graph showing the results obtained in sandwich ELISA assays with HSA alone ("■"), HSA treated with prequenched argatroban-C6 NHS ester ("*"), HSA treated with argatroban-C6 NHS ester (1:500 dilution) ("♦") or HSA reacted with argatroban-C6 NHS ester (1:1000 dilution) ("X"). Results are presented as the absorbance at 490 nm ("OD 490") versus HSA concentration in nanograms per milliliter ("ng/ml").

Figure 6 is a graph showing the results obtained in sandwich ELISA assays with hGPA alone ("Δ"), hGPA treated with prequenched argatroban-C6 NHS ester ("■") or hGPA reacted with argatroban-C6 NHS ester ("♦") employing the 5F4 monoclonal antibody. Results are presented as the absorbance at 490 nm ("OD 490") versus hGPA concentration in nanograms per milliliter ("ng/ml").

Figure 7 is a graph showing the results obtained in sandwich ELISA assays with hGPA alone ("Δ"), hGPA treated with prequenched argatroban-C6 NHS ester ("■") or hGPA reacted with argatroban-C6 NHS ester ("♦") employing the 3C10 monoclonal antibody. Results are presented as the absorbance at 490 nm ("OD 490") versus hGPA concentration in nanograms per milliliter ("ng/ml").

Figure 8 is a graph showing the results obtained in sandwich ELISA assays with hGPA alone ("Δ"), hGPA treated with prequenched argatroban-C6 NHS ester ("■") or hGPA reacted with argatroban-C6 NHS ester ("♦") employing the 3E4 monoclonal antibody. Results are presented as the absorbance at 490 nm ("OD 490") versus hGPA concentration in nanograms per milliliter ("ng/ml").

Figure 9 is a graph showing the results obtained in thrombin inhibitor assays with RSA alone ("○") or RSA reacted with argatroban-C6 NHS ester ("●"). Results are presented as the % inhibition of thrombin versus the amount of RSA employed in nM.

Figure 10 is a graph showing the results obtained in thrombin inhibitor assays with thrombin alone ("○") or erythrocyte ghosts reacted with argatroban-C6 NHS ester ("⊕"). The points on the graph wherein conjugated erythrocyte ghosts

were employed are each shown by the symbol ("⊕"), however, those points define 3 parallel lines representing (from the top of the graph to the bottom) the addition of 200 μ g, 450 μ g and 600 μ g of ghosts/ml. Results are presented as the thrombin activity versus the number of minutes at 21°C.

- 5 Figure 11 is a graph showing the results obtained demonstrating the ability of the novel thrombin inhibitors of the present invention, when covalently bound to RSA, to delay thrombin-induced platelet aggregation. Data is presented as the concentration in μ g/ml of RSA alone ("RSA") or RSA covalently bound by argatroban-C6 NHS-ester molecules ("RSA-Ar") versus the time in minutes to
- 10 achieve 50% platelet aggregation. Assays were run in duplicate and each assay is shown as a separate column at each concentration tested.

DETAILED DESCRIPTION OF THE INVENTION

- Methods and compositions are provided for the treatment of patients having disorders associated with abnormal thrombosis through inhibition of the mammalian
- 15 protein, thrombin. The method employs a novel thrombin inhibitor compound comprising a derivative of the known thrombin inhibitor argatroban, wherein the novel thrombin inhibitor compound has a chemically reactive group which reacts with available reactive functionalities on various blood components, thereby covalently bonding the derivatized thrombin inhibitor molecule to those blood
- 20 components. The chemically reactive group is at a site, so that when the thrombin inhibitor portion is bonded to the blood component, the thrombin inhibitor portion retains a substantial proportion of the parent compound's inhibitory activity. Therefore, through the covalent bonding of the subject thrombin inhibitor molecules to long-lived blood components, the effective lifetime of the thrombin inhibitor in
- 25 the host's vascular system is greatly increased.


The various sites with which the chemically reactive group of the subject thrombin inhibitor molecules may react include cells, particularly red blood cells (erythrocytes) and platelets, and proteins, such as immunoglobulins, including IgG and IgM, serum albumin, ferritin, steroid binding proteins, transferrin, thyroxin

binding protein, α -2-macroglobulin, and the like. Those proteins with which the derivatized thrombin inhibitor compounds react, which are not long-lived, will generally be eliminated from the host within about three days, so that the proteins indicated above (including the proteins of the cells) will remain at least three days, usually at least four days, and may remain five days or more, usually not exceeding 60 days, more usually not exceeding 30 days, particularly as to the half life, based on the concentration in the blood, as measured in from about 1-3 hours after administration.

For the most part, reaction will be with mobile components in the blood, particularly blood proteins and cells, more particularly blood proteins and erythrocytes. By "mobile" is intended that the component does not have a fixed situs for any extended period of time, generally not exceeding 5, more usually one minute, although some of the blood component may be relatively stationary for extended periods of time. Initially, there will be a relatively heterogeneous population of functionalized proteins and cells. However, for the most part, the population within a few days will vary substantially from the initial population, depending upon the half-life of the functionalized proteins in the blood stream. Therefore, usually within about three days or more, IgG will become the predominant functionalized protein in the blood stream.

Usually, by day 5 post-administration, IgG, serum albumin and erythrocytes will be at least about 60 mole %, usually at least about 75 mole %, of the conjugated components in blood, with IgG, IgM (to a substantially lesser extent) and serum albumin being at least about 50 mole %, usually at least about 75 mole %, more usually at least about 80 mole %, of the non-cellular conjugated components.

The derivatized thrombin inhibitor molecules of the present invention will, for the most part, have the following formula:



wherein:

- Y is a linking group having from 2-30, more usually from 2-18, preferably
 5 from 6-12 atoms in the chain, particularly carbon, oxygen, phosphorous and
 nitrogen, more particularly carbon and oxygen, where Y may be alkylene,
 oxyalkylene, or polyoxyalkylene, preferably an alkyl chain having from 2-15, more
 preferably from 6-12 carbon atoms in the alkyl chain, and the like; and
- Z is a chemically reactive group or precursor to a chemically reactive group,
 10 such as carboxy, carboxy ester, where the ester group is of 1-8, more usually 1-6
 carbon atoms, particularly a physiologically acceptable leaving group which
 activates the carboxy carbonyl for reaction with amino groups in an aqueous system,
 e.g. N-hydroxysuccinimide, isocyanate, thiolester, thionocarboxylic acid ester,
 imino ester, mixed anhydride, e.g. carbodiimide anhydride, carbonate ester,
 15 phosphoryl ester, etc. and the like.

The activatable precursor will usually be a non-oxo-carbonyl group,
 including the sulfur and nitrogen analogs thereof, such as thiono and thiol acids and
 esters and imino esters or functionalities which can be directly modified to provide
 an active functionality, e.g. cyano.

The reactive functionalities which are available on proteins for covalently bonding to the chemically reactive group of the derivatized thrombin inhibitors of the present invention are primarily amino groups, carboxyl groups and thiol groups. While any of these may be used as the target of the chemically reactive group on the thrombin inhibitor, for the most part, bonds to amino groups will be employed, particularly with the formation of amide bonds. To form amide bonds, one may use as a chemically reactive group a wide-variety of active carboxyl groups, particularly esters, where the hydroxyl moiety is physiologically acceptable at the levels required. While a number of different hydroxyl groups may be employed, the most convenient will be N-hydroxysuccinimide (NHS), and N-hydroxy sulfosuccinimide (sulfo-NHS), although other alcohols, which are functional in an aqueous medium such as blood, may also be employed. In some cases, special reagents find use, such as azido, diazo, carbodiimide anhydride, hydrazine, dialdehydes, thiol groups, or amines to form amides, esters, imines, thioethers, disulfides, substituted amines, or the like. Usually, the covalent bond which is formed should be able to be maintained during the lifetime of the blood component, unless it is intended to be a release site.

If desired, the subject conjugates may also be prepared *in vitro* by combining blood with derivatized thrombin inhibitors of the present invention, allowing covalent bonding of the derivatized thrombin inhibitors to reactive functionalities on blood components and then returning the conjugated blood to the host. Moreover, the above may also be accomplished by first purifying an individual blood component or limited number of components, such as red blood cells, immunoglobulins, serum albumin, or the like, and combining the component or components *in vitro* with the chemically reactive thrombin inhibitors. The functionalized blood or blood component may then be returned to the host to provide *in vivo* the subject therapeutically effective conjugates. The blood also may be treated to prevent coagulation during handling *in vitro*.

When conjugates are prepared *in vitro*, the ratio of derivatized thrombin inhibitor to blood components will vary widely, depending upon whether whole

blood or just a purified component is used as a bonding site for the derivatized thrombin inhibitor. For reacting with whole blood, one will normally have a ratio of derivatized thrombin inhibitor to blood of about 38 micrograms per ml to about 300 micrograms per ml, respectively, while the ratio of derivatized thrombin inhibitor to 10^9 cells will be in the range of about 7.6 micrograms to about 300 micrograms, while the ratio of derivatized thrombin inhibitor to 1 mg of protein will be in the range of about 38 micrograms to about 300 micrograms.

The nature of the thrombin inhibitor compound may provide for random bonding to the long lived blood components or, to varying degrees, targeted bonding to a restricted class of blood components. For random bonding, the distribution of the thrombin inhibitor compound will be based on the relative proportion of active sites for bonding of the blood components, the mode of administration and whatever preferential association the thrombin inhibitor may have. For targeted bonding, a part of the thrombin inhibitor compound will be a group which preferentially non-covalently binds to one or more sites present on one or more of the blood components. For this purpose, entities which are known to complex with particular blood components may be used. Alternatively, one may prepare a combinatorial library and screen for members of the library which provide the desired blood component association spectrum. For the most part, random bonding will be employed.

To the extent that targeted bonding is employed, the choice of the long lived blood component will be affected, at least in part, by the desired lifetime for the drug and the availability of the blood component for bonding to the derivatized thrombin inhibitor.

A long lived blood component has a half life of at least about 12 hours, usually at least about 48 hours, preferably at least about 5 days, desirably at least about 10 days and more desirably at least about 20 days or more. Generally, half lives are determined by serial measurements of whole blood, plasma or serum levels of the compound following labeling of the compound with an isotope (e.g. ^{131}I , ^{125}I , ^{51}Cr , ^3H , etc.) or fluorochrome and injection of a known quantity of labeled

compound intravascularly. Included are red blood cells (half life ca. 60 days), platelets (half life ca. 4-7 days), endothelial cells lining the blood vasculature, and long lived blood serum proteins, such as albumin, steroid binding proteins, ferritin, α -2-macroglobulin, transferrin, thyroxin binding protein, immunoglobulins, especially IgG, etc. In addition to preferred half lives, the subject components are preferably in cell count or concentration sufficient to allow binding of therapeutically useful amounts of the compound of the present invention. For cellular long lived blood components, cell counts of at least 2,000/ μ l and serum protein concentrations of at least 1 μ g/ml, usually at least about 0.01 mg/ml, more usually at least about 1 mg/ml, are preferred.

The cellular long lived blood components to which the subject derivatized thrombin inhibitors bond are present in high number in the vascular system. Platelets are present in from about $1-4 \times 10^5$ / μ l, while red blood cells are present in about $4-6 \times 10^6$ / μ l. The cells have a long half life and the binding to a surface membrane protein of the cells appears not to result in endocytosis. Preferred cells have a wide distribution in capillaries and tissue and express specific binding sites on the cell surface associated with their specific differentiation. In addition to *in vivo* administration of the subject derivatized thrombin inhibitors, in the case of red blood cells and platelets, these cells may be readily collected, combined with the conjugate *in vitro*, and then administered to the host. The cells will normally be autologous or allogeneic, but in some instances may even be xenogeneic.

Suitable erythrocyte binding site containing molecules include glycophorin A, B and C, Band 3 and Rhesus blood group antigens. Preferred erythrocyte binding sites are abundantly expressed on the erythrocyte with copy numbers of at least 1,000, preferably at least 10,000, more preferably at least 100,000 per cell, desirably are tethered at least about 0.5, preferably at least about 1 nm above the bilayer surface and do not facilitate *per se* cell deformation when the derivatized thrombin inhibitor molecule is bound to the cell (e.g. the binding will be selected so as not to be a key component of the cytoskeleton). Binding sites of the erythrocyte surface glycoprotein glycophorin A and erythrocyte binding sites comprising sialic

acid are examples of preferred binding sites. Preferred platelet binding sites include GPIIa, GPIIb, GPIIIa and GPIV. Desirably, upon bonding to the target, deformation of the long-lived blood component, e.g. erythrocyte or platelet, does not occur.

5 The derivatized thrombin inhibitors of the present invention will usually be administered as a bolus, but may be introduced slowly over time by infusion using metered flow, or the like. Alternatively, although less preferable, blood may be removed from the host, treated *ex vivo*, and returned to the host. The derivatized thrombin inhibitors will be administered in a physiologically acceptable medium,
10 e.g. deionized water, phosphate buffered saline (PBS), saline, aqueous ethanol or other alcohol, plasma, proteinaceous solutions, mannitol, aqueous glucose, alcohol, vegetable oil, or the like. Other additives which may be included include buffers, where the media are generally buffered at a pH in the range of about 5 to 10, where the buffer will generally range in concentration from about 50 to 250 mM, salt,
15 where the concentration of salt will generally range from about 5 to 500 mM, physiologically acceptable stabilizers, and the like. The compositions may be lyophilized for convenient storage and transport.

 The subject derivatized thrombin inhibitors will for the most part be administered parenterally, such as intravascularly (IV), intraarterially (IA),
20 intramuscularly (IM), subcutaneously (SC), or the like. Administration may in appropriate situations be by transfusion. In some instances, where reaction of the active functional group is relatively slow, administration may be oral, nasal, rectal, transdermal or aerosol, where the nature of the conjugate allows for transfer to the vascular system. Usually a single injection will be employed although more than
25 one injection may be used, if desired. The derivatized thrombin inhibitors may be administered by any convenient means, including syringe, trocar, catheter, or the like. The particular manner of administration will vary depending upon the amount to be administered, whether a single bolus or continuous administration, or the like. Preferably, the administration will be intravascularly, where the site of introduction
30 is not critical to this invention, preferably at a site where there is rapid blood flow,

e.g. intravenously, peripheral or central vein. Other routes may find use where the administration is coupled with slow release techniques or a protective matrix. The intent is that the subject compound be effectively distributed in the blood, so as to be able to react with the blood components. The concentration of the conjugate will
5 vary widely, generally ranging from about 1 pg/ml to 50 mg/ml. The total administered intravascularly will generally be in the range of about 0.1 mg/ml to about 10 mg/ml, more usually about 1 mg/ml to about 5 mg/ml.

The manner of producing the derivatized thrombin inhibitors of the present invention will vary widely, depending upon the nature of the various elements
10 comprising the molecule. The synthetic procedures will be selected so as to be simple, provide for high yields, and allow for a highly purified product. Normally, the chemically reactive group will be created as the last stage, for example, with a carboxyl group, esterification to form an active ester will be the last step of the synthesis. An illustrative method for the production of the derivatized thrombin
15 inhibitors of the present invention is shown in Figure 1.

By bonding to long-lived components of the blood, such as immunoglobulin, serum albumin, red blood cells and platelets, a number of advantages ensue. The inhibition of the thrombin protein is extended for days to weeks. Only one administration need be given during this period of time. Greater specificity can be
20 achieved, since the active compound will be primarily bound to large molecules, where it is less likely to be taken up intracellularly to interfere with other physiological processes.

The blood of the mammalian host may be monitored for the presence of the thrombin inhibitor one or more times. By taking a portion or sample of the blood of
25 the host, one may determine whether the thrombin inhibitor has become bound to the long lived blood components in sufficient amount to be therapeutically active and, thereafter, the level of thrombin inhibition activity in the blood. If desired, one may also determine to which of the blood components the thrombin inhibitor molecule is bound.

The derivatized thrombin inhibitors of the present invention will find use in a variety of different applications. For example, the novel thrombin inhibitors of the present invention are useful for the treatment and/or prevention of disorders associated with abnormal thrombosis. The subject thrombin inhibitor molecules are
5 useful for inhibiting the production of thromboses, accelerating the dissolution of existing thromboses and for maintaining and/or improving blood circulation. The subject derivative molecules will also find use, for example, for treatment after surgery, after myocardial infarction, arteritis of the legs, deep venous thrombosis, pulmonary embolism, and the like.

10 The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Example 1: Synthesis of Extended Lifetime Derivatized Thrombin Inhibitor Molecules

15 *Materials and Methods:* The synthesis of various derivatized extended lifetime thrombin inhibitor (argatroban-derived) molecules is schematically diagramed in Figure 1 and is described below.

(1) Synthesis of Methyl 12-Aminododecanoate (compound YS-004-17).

To a suspension of 12-aminododecanoic acid (5.00 g, 23.3 mmol) in anhydrous
20 MeOH (90 mL) was introduced hydrogen chloride gas for 25 minutes, during which time the suspension became clear. The solution was then stirred at room temperature for 3 hours and the solvent was removed in vacuo. The white solid residue was dissolved in H₂O. Solid NaHCO₃ was added to neutralize the solution to pH 8-9. The white precipitates thus formed were collected by vacuum filtration
25 (5.20 g) (Yield: 98%).

¹HNMR (MeOH-d₄, 300 MHz) δ 3.67 (s, 3H, OCH₃), 2.68 (t, 2H, J=7.1 Hz, NCH₂), 2.30 (t, 2H, J=7.5 Hz, CH₂CO₂), 1.68 - 1.56 (m, 2H, CH₂), 1.50 - 1.38 (m, 2H, CH₂), 1.27 (br. s, 12 H, (CH₂)₆), 1.20 - 0.90 (m, 2H, CH₂).

(2) Synthesis of Methyl 6-Aminohexanoate (compound YS-004-58).

5 To a suspension of 6-aminocaproic acid (3.00 g, 22.9 mmol) in anhydrous MeOH (60 mL) was introduced hydrogen chloride gas for 25 minutes, during which time the suspension became clear. The solution was then stirred at room temperature for 5 hours and MeOH was removed in vacuo. The residue was recrystallized from THF to give a white solid (3.10 g). (Yield: 75 %).

10 ¹HNMR (MeOH-d₄, 300 MHz) δ 3.66 (s, 3H, OCH₃), 2.92 (t, 2H, J=7.7 Hz, NCH₂), 2.37 (t, 2H, J=7.2 Hz, CH₂CO₂), 1.74 - 1.60 (m, 4H, CH₂CH₂), 1.48 - 1.36 (m, 2H, CH₂)

3. Synthesis of Argatroban-C12 Methyl Ester (compound YS-004-67).

15 To a solution of argatroban monohydrate (300 mg, 0.570 mmol) and methyl 12-aminododecanoate (compound YS-004-17) (132 mg, 0.576 mmol) in anhydrous DMF (15 mL) was added HBTU (258 mg, 0.680 mmol). Stirring was continued at room temperature for 16 hours. The precipitates formed during the reaction were filtered off and DMF was removed by vacuum distillation. The residue was purified by preparative TLC using solvents CH₂Cl₂/MeOH/NH₃ (90/10/1, v/v) to give the
20 titled compound (140 mg) (Yield: 28%). ¹HNMR (MeOH-d₄, 300 MHz).

4. Synthesis of Argatroban-C6 Methyl Ester (compound YL-015-13).

To a solution of argatroban monohydrate (100 mg, 0.190 mmol) and methyl 6-aminohexanoate hydrochloride (compound YS-004-58) (35 mg, 0.193 mmol) in anhydrous DMF (5 mL) was added triethylamine (23 mg, 0.23 mmol), followed by
25 addition of HBTU (86 mg, 0.23 mmol). Stirring was continued at room temperature for 20 hours. The precipitates formed during the reaction were filtered off and DMF was removed by vacuum distillation. The residue was purified by preparative

TLC using solvents $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_3$ (90/10/1, v/v) to give the titled compound (78 mg) (Yield: 53%). $^1\text{HNMR}$ ($\text{MeOH}-d_4$, 300 MHz).

5. Synthesis of Argatroban-C12 Free Acid (compound YL-015-10). A solution of compound YS-004-67 (225 mg, 0.260 mmol) in MeOH (4.2 mL) and 1 M aqueous NaOH (0.87 mL) was stirred at room temperature for 24 hours. MeOH was removed in vacuo to give a cloudy solution, to which more H_2O was added until the solution became clear. The solution was acidified with 1 N HCl to pH 3.0 while being cooled at 0°C to give a white precipitate, which was collected by vacuum filtration to afford the titled compound (105 mg). The filtrate was extracted with n-butanol (4 x 4 mL). The combined butanol solution was washed with H_2O (to pH 5.0) and concentrated in vacuo azeotropically with H_2O to give another portion of the compound (58 mg) (Yield: 85%). $^1\text{HNMR}$ ($\text{MeOH}-d_4$, 300 MHz).

6. Synthesis of Argatroban-C6 Free Acid (compound YL-015-15). A solution of compound YL-015-13 (124 mg, 0.159 mmol) in MeOH (3mL) and 1 M aqueous NaOH (0.55 mL) was stirred at room temperature for 33 hours. The reaction was worked up by the same procedure as described for the preparation of compound YL-015-10, to give the titled compound (76 mg) (Yield: 73%). $^1\text{HNMR}$ ($\text{MeOH}-d_4$, 300 MHz).

7. Synthesis of Argatroban-C12 NHS Ester (compound YL-015-11). To a solution of compound YL-015-10 (40 mg, 0.054 mmol) and N-hydroxysuccinimide (13 mg, 0.11 mmol) was added diisopropylethylamine (7.4 mg, 0.057 mmol), followed by addition of HBTU (43 mg, 0.11 mmol). The reaction mixture was stirred at room temperature for 36 hours. DMF was removed by vacuum distillation and the residue was dissolved in MeOH (4 mL). The MeOH solution was filtered to remove the insolubles, the filtrate was concentrated in vacuo, and the residue was dissolved in a minimum amount of MeOH. H_2O was then added to induce

precipitation and the precipitate was dried on vacuum to give the titled compound (19 mg) (Yield: 42%).

The yield of the reaction was later improved by using EDC as the coupling reagent, as exemplified below. To a solution of compound YL-015-10 (40 mg, 0.054 mmol) and N-hydroxysuccinimide (13 mg, 0.115 mmol) in anhydrous DMF (3 mL), was added EDC (31 mg, 0.162 mmol). The solution was stirred at room temperature for 24 hours. DMF was removed by vacuum distillation and the residue was further dried on high vacuum. The residue was then dissolved in a minimum amount of MeOH (0.12 mL) and H₂O (3.2 mL) was added to induce precipitation. The precipitates were washed with H₂O (3 x 0.8 mL) and dried on vacuum to give a solid product (31 mg) (Yield: 69%). ¹HNMR (MeOH-d₄, 300 MHz).

8. Synthesis of Argatroban-C6 NHS Ester (compound YL-015-35). To a solution of compound YL-015-15 (78 mg, 0.12 mmol) and N-hydroxysuccinimide (29 mg, 0.25 mmol) in anhydrous DMF (6 mL) was added EDC (72 mg, 0.38 mmol). The solution was stirred at room temperature for 20 hours and DMF was removed by vacuum distillation. The residue was dissolved in a minimum amount of MeOH (0.4 mL) and H₂O (1.2 mL) was added to induce precipitation. The precipitates were washed with H₂O (3 x 0.7 mL) and dried on vacuum to afford a solid product. The solid product was further purified by recrystallization from acetone/ether (1/1, v/v) to give a white solid product (62 mg) (Yield: 69%). ¹HNMR (MeOH-d₄, 300 MHz).

9. Synthesis of Argatroban-C12 Sulfo-NHS Ester (compound YL-015-23). Compound YL-015-10 (10.0 mg, 13.5 μ mol), sulfo-NHS (6.2 mg, 28.3 μ mol) and EDC (8.2 mg, 42.5 μ mol) were dissolved in anhydrous DMF (0.8 mL). The reaction mixture was stirred at room temperature for 2 days and DMF was removed by vacuum distillation. The residue was washed with a small amount of H₂O, then

with EtOAc and acetone, to give a white solid product (9.2 mg) (Yield: 77%).

¹HNMR (MeOH-d₄, 300 MHz).

Results: A one-step derivatization of the thrombin inhibitor argatroban with a linking polypeptide and a chemically reactive group has been realized. Briefly, the free carboxylate group on the argatroban molecule is activated with HBTU, presumably via formation of N-hydroxybenzotriazole ester, which then reacts with the amino group of the linking polypeptide to give the desired adduct. A side-product with a molecular weight corresponding to that of argatroban minus a water molecule, was also observed by mass spectroscopic analysis. This by-product is probably derived from an internal nucleophilic attack on the activated ester. If the argatroban molecule was pre-activated with HBTU before the addition of the nucleophilic amino ester, more of the side product would be produced. Therefore, the amino ester and argatroban were mixed prior to addition of HBTU in the reaction. The product was purified on preparative TLC plates. Although the yields are relatively low (28-53%), the simple one-step linking polypeptide placement without protecting those functional groups on argatroban is very satisfactory.

Two amino aliphatic acid methyl esters with 6 and 12 methylene units spans were chosen as the linking polypeptides because of their structural stability and simplicity. The linking polypeptides of variable lengths will provide information on length requirement for optimal drug presentation to its target.

Subsequent hydrolysis of the methyl esters on the linking polypeptides under alkaline condition went smoothly to give the corresponding acid in 73-85% yields. Treatment of the free acid with HBTU in the presence of N-hydroxysuccinimide and DIEA afforded the desired NHS ester in 42% yield. The yield was later improved to 69% by using EDC as the coupling reagent. The formation of the NHS ester was confirmed by ¹HNMR and mass spectroscopy.

Example 2: Derivatized Argatroban Molecules are Bioavailable after Covalent Attachment to Rabbit Erythrocytes

Material and Methods: Rabbit erythrocytes were conjugated with the Argatroban-C6 NHS ester compound (compound YL-015-35). To do so, rabbit erythrocytes were isolated from fresh, citrated blood. In brief, an aliquot of blood was centrifuged for 5 minutes at 1800 rpm (Sorvall RC-5B, SH-3000 rotor). The buffy coat was pipetted off the top layer of the cell pellet and the remaining erythrocytes were washed four times with PBS, pH 7.4. Before the last wash, an aliquot of cells was removed for counting. The washed erythrocytes were resuspended at a density of 1×10^9 cells/mL. The total volume of cells labeled per sample was 3 mL. Cells were reacted at room temperature for 45 minutes with gentle agitation with one of the following reagents: (1) sham, 0.5% DMSO/PBS; (2) 100 μ M argatroban C6-free acid (compound YL-015-15) in 0.5% DMSO/PBS; (3) 10 μ M argatroban C6-NHS ester (compound YL-015-35) in 0.5% DMSO/PBS; (4) 50 μ M argatroban C6-NHS ester (compound YL-015-35) in 0.5% DMSO/PBS; (5) 100 μ M argatroban C6-NHS ester (compound YL-015-35) in 0.5% DMSO/PBS; and (6) 100 μ M sulfo-NHS-LC-biotin (Pierce, catalog no. 21335) in 0.5% DMSO/PBS. After the labeling reaction, the cells were centrifuged 4 minutes at 1800 rpm and the supernatant was discarded. The cells were resuspended in 10 ml of 0.5% DMSO/PBS and pelleted. The cells were washed one more time with 10 ml of PBS.

To quench any remaining reactive esters, the cells were then resuspended in 6 mg/mL BSA/PBS (Sigma, A-2934, lot 93HO291) and gently agitated at room temperature for 30 minutes. After quenching, the cells were washed five times with PBS. Cell yields were determined by cell counting.

After conjugation, the cells were hypotonically lysed and the ensuing membrane (ghost) and cytosol fractions were assayed by immunoblotting and ELISA. Specifically, conjugated erythrocyte pellets were chilled on ice for 5 minutes. Cells were then lysed on ice with 12 ml of ice-cold 5 mM phosphate buffer, pH 8.0 (PB) containing 1 mM Pefabloc and 40 μ M leupeptin. Lysates were briefly vortexed and then centrifuged for 20 minutes at 4°C at 15,000 rpm (SS-34, Sorvall RC-5B). The supernatant (hemolysate) was pipetted off the pellet, labeled and stored at 4°C. The pellets (ghosts) were washed four times with 12 ml of cold

PBS and centrifuged as above. The protein content of the ghosts and hemolysates was determined by using the Micro BCA kit (Pierce; catalog no. 23231). Cell fractions were stored at -80°C.

Samples were then solubilized in 2X reducing cocktail (5% SDS, 50%
5 glycerol, 0.5 M 2-mercaptoethanol in 0.25 M Tris-HCl, pH 6.8). After a 5 minute treatment at 100°C and then brief cooling, samples were resolved by SDS-PAGE on 10% polyacrylamide mini-gels. After electrophoretic transfer to nitrocellulose and brief Ponceau S staining, the blots were blocked with Blotto (5% instant non-fat dry milk in PBS, pH 7.4) for 2 hours at room temperature. The blots were then washed
10 four times with TBS-T (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.25% Tween-20) and incubated for 2 hours at room temperature with a 1:1000 dilution of rabbit serum in TBS-T. Blots were then washed four times with TBS-T as above and incubated with biotinylated anti-rabbit IgG antibodies (Vector, BA-1000) for 1 hour at room temperature. Blots were washed as above and then were incubated with
15 ABC-HRP (Vector) for 30 minutes at room temperature. After washing, blots were visualized with the metal enhanced DAB substrate kit (Pierce, catalog no. 34065).

Results: The results of the above described experiments demonstrated that numerous erythrocyte membrane proteins were covalently modified with the derivatized argatroban-C6 NHS ester molecule. By contrast, the presence of
20 derivatized argatroban molecules on cytosolic proteins was at the limit of detection, suggesting that this thrombin inhibitor compound is an effective reagent for covalently bonding to proteins located on the outside of cells and, ultimately, for the delivery of drugs. Moreover, by a capture ELISA assay, it was observed that a portion of the thrombin inhibitor-labeled proteins belong to the glycophorin family
25 of proteins.

Example 3: Mass Spectrometric Analysis of Derivatized Argatroban Conjugation to Human Serum Albumin (HSA) and Rabbit Serum Albumin (RSA).

Materials and Methods: Mass spectrometry was used to support covalency of the bonding of derivatized argatroban molecules to the proteins human serum albumin (HSA) and rabbit serum albumin (RSA) as well as to quantitate the number of conjugated argatroban molecules covalently bound to the proteins. All samples were analyzed using a high performance liquid chromatograph (HPLC) coupled in-line to an electrospray ionization (ESI) mass spectrometer (MS) which is termed HPLC/ESIMS. Some samples were also analyzed using a matrix-assisted laser desorption ionization (MALDI) time-of-flight (TOF) mass spectrometer which is termed (MALDI-TOFMS).

Samples for HPLC/ESIMS were either prepared as duplicate reaction samples or were part of the same reaction samples which were used in the ELISA assays described below. These samples were injected directly only the HPLC/ESIMS without any manipulation other than dilution with water, where the PBS, DMSO, and unreacted derivative molecules are separated from the protein-argatroban derivative molecule conjugate. Samples for MALDI-MS were first HPLC-purified and mixed 1:1 directly on the stainless steel analysis plate with a matrix of 10 mg/ml sinnapinic acid in 50% acetonitrile/50% water. The mixture was then dried with a gentle flow of air to allow for crystallization and inserted into the instrument for laser ionization.

The HPLC is a Hewlett Packard 1090 Series II liquid chromatogram with a diode array detector. The column used for separation is a Brownlee aquapore OD-300 reversed phase C18 column, 1 mm x 10 cm, 300 Å pore size, 7 µm particle diameter. The mass spectrometer to which the HPLC is connected using fused Silica capillary tubing is a Sciex API-300 triple quadrupole mass spectrometer with an ion-spray source to allow for atmospheric pressure ionization of a liquid flowing continuously into the instrument. The MALDI-TOFMS is a Perceptive Biosystems Voyager Elite DE instrument run in the linear mode.

Results:

(1) Argatroban-C6 NHS Ester vs. Argatroban-C12 NHS Ester, 20:1
Molar Excess of Ester vs. HSA or RSA.

HPLC/ESIMS of HSA (0.33 $\mu\text{g}/\mu\text{l}$, 5 μM) reacted for 1 hour at room
5 temperature with 100 μM argatroban-C6 NHS ester (compound YL-015-35)
indicated a covalent addition of 1-8 argatroban derivative molecules per HSA
molecule. RSA (0.30 $\mu\text{g}/\mu\text{l}$, 4.5 μM) reacted for 1 hour at room temperature with
100 μM argatroban-C6 NHS ester (compound YL-015-35) also indicated a covalent
addition of 1-8 argatroban derivative molecules per RSA molecule. However, with
10 the argatroban-C12 NHS ester (compound YL-015-11) under the same conditions,
only 1-5 argatroban derivatives are covalently added per molecule of HSA or RSA.
These results suggest that the argatroban derivative molecule having a linking
polypeptide of 6 carbon atoms acts to provide more efficient bonding to available
reactive functionalities on both HSA and RSA than does an argatroban derivative
15 molecule having a linking polypeptide of 12 carbon atoms.

(2) HSA vs. RSA, Argatroban-C12 NHS Ester, 1:10 Molar Deficiency of
Ester vs. Protein.

HPLC/ESIMS of HSA (0.33% $\mu\text{g}/\mu\text{l}$, 5 μM) reacted for 1 hour at room
temperature with 0.5 μM argatroban-C12 NHS ester (compound YL-015-11)
20 indicated a covalent addition of 0-4 argatroban derivative molecules per HSA
molecule. RSA (0.30 $\mu\text{g}/\mu\text{l}$, 4.5 μM) reacted for 1 hour at room temperature with
0.5 μM argatroban-C12 NHS ester (compound YL-015-11) indicated a covalent
addition of 0-3 argatroban derivative molecules per RSA molecule, or slightly less
covalent labeling than obtained with the HSA protein.

25 (3) 15 μM vs. 30 μM RSA, Argatroban-C6 NHS Ester, 10-12:1 Molar
Excess of Ester vs. RSA.

HPLC/ESIMS of RSA (1.0 $\mu\text{g}/\mu\text{l}$, 15 μM) reacted for 1 hour at room
temperature with 200 μM argatroban-C6 NHS ester (compound YL-015-35)

indicated a covalent addition of 1-9 argatroban derivative molecules per RSA molecule. RSA (2.0 $\mu\text{g}/\mu\text{l}$, 30 μM) reacted for 1 hour at room temperature with 300 μM argatroban-C6 NHS ester (compound YL-015-35) also indicated a covalent addition of 1-9 argatroban derivative molecules per RSA molecule. These results were confirmed by MALDI-MS analysis of these two samples which gives a single broad peak centered on the average molecular weight of the sample. Based on these average molecular weights, the 15 $\mu\text{M}/200 \mu\text{M}$ RSA/argatroban derivative sample yielded an average of 5.6 argatroban derivative molecules added per RSA molecule (range of 1-10 added) and the 30 $\mu\text{M}/300 \mu\text{M}$ RSA/argatroban derivative sample yielded an average of 5.4 argatroban derivative molecules added per RSA molecule (range of 1-10 added).

(4) Concentration Study of 1-100 μM Argatroban-C6 NHS Ester Reacted with 4.5 μM RSA.

HPLC/ESIMS of RSA (0.30 $\mu\text{g}/\mu\text{l}$, 4.5 μM) reacted for 1 hour at room temperature with argatroban-C6 NHS ester (compound YL-015-35) (1, 10, 15, 20, 25, and 100 μM) yielded a linear covalent addition of argatroban derivative molecules to each molecule of RSA as indicated by the following results:

- 1 μM adds no detectable argatroban derivative molecules
- 10 μM adds 1 argatroban derivative molecule to ~50% of the RSA molecules
- 15 μM adds 0-3 argatroban derivative molecules per RSA molecule (majority of RSA molecules are +1)
- 20 μM adds 1-3 argatroban derivative molecules per RSA molecule (majority of RSA molecules are +1 and +2)
- 25 μM adds 1-4 argatroban derivative molecules per RSA molecule (majority of RSA molecules are +1 and +2)
- 100 μM adds 2-10 argatroban derivative molecules per RSA molecule (no major species).

Example 4: Sandwich ELISA Assays to Assess the Relative Bioavailability of Derivatized HSA to Thrombin.

Materials and Methods: Human serum albumin (HSA, Sigma Cat. #A-8763) at a concentration of 333 $\mu\text{g/ml}$ or rabbit serum albumin (RSA, Sigma Cat #A-9438) at a concentration of 300 $\mu\text{g/ml}$ was reacted with 100 μM argatroban-C6 or -C12 NHS ester (compounds YL-015-35 or YL-015-11, respectively) in PBS, pH 7.4, for 1 hour at room temperature. The reaction was quenched by the addition of hydroxylamine, pH 7.8 to a final concentration of 50 mM and incubation at room temperature for 10 minutes. Prequenched negative control samples were of the same composition except that the argatroban NHS ester was reacted with hydroxylamine for 10 minutes prior to the addition of HSA or RSA. Finally, the HSA or RSA only sample had DMSO added to 1% to mimic the addition of argatroban NHS ester solutions and was incubated and quenched the same as the other reactions.

Rabbit anti-HSA (Boehringer/Mannheim, catalog no. 605001) or goat anti-RSA (Cappel, catalog no. 55629) antibodies were diluted 1:5000 in PBS, pH 7.4 and 100 $\mu\text{l/well}$ was aliquotted into a NUNC Maxisorp F96 plates (catalog no. 439454). The plate was incubated overnight at 4°C, then blocked by the addition of 200 $\mu\text{l/well}$ of 1% BSA/PBS and incubated at room temperature for 1 hour. The plate was then washed 5 times by submersion in PBS, pH 7.4.

The various HSA/argatroban derivative or RSA/argatroban derivative samples were serially diluted in 1% BSA/PBS (1:100 to 1:50,000) and 100 $\mu\text{l/well}$ was added to duplicate wells of each sample dilution. Samples were incubated on the plates for 2 hours at room temperature and the plates were then washed as above.

Thrombin (Via Enzymes Systems, 11.4 mg/ml) was diluted to 9.4 $\mu\text{g/ml}$ in PBS, pH 7.4, with 0.1% BSA/0.1% PEG 8000 (Sigma, catalog no. P-2139) and 100 $\mu\text{l/well}$ was added. The plates were incubated at room temperature for 1 hour and washed as above.

Mouse anti-thrombin (American Diagnostics, catalog no. EST-7), an antibody thought to bind away from the active site of thrombin, was diluted to 1 $\mu\text{g/ml}$ in PBS, pH 7.4, with 0.1% BSA/0.1% PEG 8000 and 100 $\mu\text{l/well}$ was added

to all wells. The plates were incubated at room temperature for 30 minutes and washed as above.

Biotinylated rabbit anti-mouse IgG (mouse gamma specific, Zymed, catalog no. 61-6540) was diluted 1:1000 in PBS, pH 7.4, with 0.1 % BSA and 1 % PEG 8000 and 100 μ l/well was added to all wells. The plates were incubated at room temperature for 30 minutes and washed as above.

Next, 100 μ l/well of ABC-HRP (Vector, catalog no. PK4000) was added, each component diluted 1:500 in PBS, pH 7.4, with 0.1 % TWEEN 20 and incubated 30 minutes at room temperature prior to use. PEG 8000 was added to 0.1 % just before addition of ABC-HRP to the plates. The plates were incubated with ABC-HRP for 30 minutes at room temperature and were then washed 10 times by submersion in PBS, pH 7.4.

Alternatively to adding biotinylated rabbit anti-mouse IgG and the ABC-HRP, the assay was simplified and background reduced by adding goat anti-mouse IgG conjugated with HRP (Jackson ImmunoResearch, catalog no. 115-035-146) diluted 1:500 in HRP diluent (Medix, catalog no. RIH4203) and 100 μ l/well added. The plates were incubated at room temperature for 30 minutes and were then washed 10 times by submersion in PBS, pH 7.4,

Finally, 100 μ l/well of o-phenylenediamine dihydrochloride (OPD, Sigma, catalog no. P-3804) was added at 0.5 mg/ml in citrate-phosphate buffer, pH 5.3 with 0.015 % H_2O_2 and incubated at room temperature for 30 minutes. After incubation, 200 μ l/well of 2 N sulfuric acid (VWR, catalog no. VW3S00-1) was added and absorbance was read at OD₄₉₀ in a SpectraMax plate reader (Molecular Devices) after agitating the plate for 5 seconds.

Results: The results obtained from the above sandwich ELISA assays are presented in Figures 2, 3 and 4. The data presented in Figure 2 demonstrates that there is a significant increase of OD₄₉₀ in wells incubated with samples containing HSA reacted with argatroban-C6 or -C12 NHS ester (compounds YL-015-35 and YL-015-11, respectively) as compared to samples containing prequenched

argatroban NHS ester or HSA alone. A significant signal above background was detected at approximately 10 ng/ml for both the C6 and the C12 derivatized compounds but the absolute signals for the two compounds are very different with the C6 having a significantly higher OD (approx 6-7 fold at saturation). These data
5 suggest that the argatroban NHS ester derivative molecules have covalently bound to the HSA protein in such a way that it is able to interact and bind with thrombin which, in turn, can then be detected by an anti-thrombin antibody. These data, therefore, suggest that the argatroban derivatives covalently bound to the HSA protein is capable of binding to and inhibiting thrombin.

10 In the case of RSA, only the argatroban-C6 NHS ester derivative has been detected in an ELISA format (see Figure 3). A significant signal above background was detected at approximately 30 ng/ml for the argatroban-C6 derivative. In this assay, the absolute signal is lower than that obtained with HSA. This maybe the result of differences in the assay due to the capture antibody, to differences in the
15 extent and availability of labeling, or both.

Covalency of the bond between the argatroban NHS ester and the HSA or RSA protein was supported by mass spectrometry data (obtained from the duplicate reaction samples or the rest of the same reaction sample, described above) that showed that the argatroban derivative molecules had created covalent adducts on the
20 majority of the HSA or RSA proteins present in the samples.

Human glycophorin A protein (hGPA) has also been reacted with the argatroban-C6 NHS ester derivative (compound YL-015-35) under similar conditions as for the RSA protein described above. The results of these studies are presented in Figure 4. As is shown in Figure 4, the hGPA protein reacted with the
25 argatroban-C6 NHS derivative and was shown by ELISA to bind thrombin to give a detectable signal at approximately 30 ng/ml. The ELISA assay was identical to the one described for HSA and RSA above with the exception that mouse anti-hGPA (BioAtlantic/CRTS, mAb 5F4), diluted to 10 µg/ml in 0.1 M sodium acetate, pH 4.5, was used to capture the NHS-argatroban derivative reacted hGPA protein.

The results of the above experiments clearly demonstrate that the argatroban derivative molecules of the present invention not only covalently bond to reactive functionalities on various vascular-associated proteins, but do so in a way not to inhibit the ability of the derivative molecule to bind to and inhibit thrombin.

5 Keyhole limpet cyanin (KLH, Sigma, catalog no. R-5755) has also been reacted with argatroban-C12 NHS ester (compound YL-015-11) under similar conditions as for the HSA protein described above. The KLH protein reacted with argatroban-C12 NHS ester (compound YL-015-11) was shown by ELISA assay to bind to thrombin and give a detectable signal at approximately 100 ng/ml. The
10 ELISA assay was identical to the one described above for HSA and RSA above with the exception that rabbit anti-KLH (Cappel, catalog no. 55966) diluted 1:5000 in PBS, pH 7.4 was used to capture the NHS-argatroban derivative reacted KLH. Because of the extremely heterogeneous nature of the KLH preparation, it was not possible to analyze these samples by mass spectrometry. However, similar material
15 (reaction containing KLH at 2 mg/ml and argatroban-C12 NHS ester at 3.3 μ M) was used to generate polyclonal antibodies to the argatroban derivative, thereby confirming the covalent modification of the KLH protein.

Example 5: Sandwich ELISA Assays Using Polyclonal Antibodies to Evaluate
HSA, hGPA and Rabbit Erythrocyte Ghosts Conjugated with
20 Argatroban-C6 NHS Ester.

Materials and Methods: Human serum albumin (HSA, Sigma catalog no. A-8763) or human glycoporphin A (hGPA) protein at a concentration of 300 μ g/ml was reacted with 100 μ M argatroban-C6 NHS ester (compound YL-015-35) in PBS, pH 7.4, for 1 hour at room temperature. The reaction was quenched by adding
25 hydroxylamine, pH 7.8 to a final concentration of 50 mM and incubating at room temperature for 10 minutes. Prequenched negative control samples were of the same composition except that the argatroban-C6 NHS ester derivative was reacted with hydroxylamine for 10 minutes prior to the addition of HSA or hGPA protein.

Finally, the HSA or hGPA only samples had DMSO added to 1% to mimic addition of argatroban derivative solutions and was incubated and quenched the same as other reactions.

Rabbit anti-HSA monoclonal antibody (Boehringer/Mannheim, catalog no. 5 605001) diluted 1:5000 in PBS, pH 7.4 or mouse anti-hGPA monoclonal antibody (BioAtlantic/CRTS, mAb 5F4, diluted to 10 µg/ml in 0.1 M sodium acetate, pH 4.5 or mAb 3C10 diluted 1:500 or mAb 3E4 diluted 1:1000 in PBS, pH 7.4 - each antibody recognizes a different epitope of hGPA), were used to capture respective proteins by aliquotting 100 µl/well into a NUNC Maxisorp F96 plate (catalog no. 10 439454). The plates were incubated overnight at 4°C, were then blocked by the addition of 200 µl/well of 1% BSA/PBS and incubated at room temperature for 1 hour. The plates were then washed 5 times by submersion in PBS, pH 7.4.

The various HSA/argatroban derivative or hGPA/argatroban derivative samples were serially diluted in 1% BSA/PBS (1:100 to 1:50,000) and 100 µl/well 15 was added to duplicate wells for each sample dilution. Samples were incubated on the plates for 2 hours at room temperature and then were washed as above.

Rabbit anti-KLH-argatroban antibody was diluted 1:500 or 1:1000 in 1% BSA/PBS, pH 7.4 and 100 µl/well added to each well. The plates were then incubated at room temperature for 30 minutes and washed as above.

20 Biotinylated goat anti-rabbit IgG (Vector, catalog no. BA1000) was diluted 1:1000 in 1% BSA/PBS, pH 7.4 and 100 µl/well added to all wells. The plates were incubated at room temperature for 30 minutes and washed as above.

Next, 100 µl/well of ABC-HRP (Vector, catalog no. PK4000) was added, each component diluted 1:500 in PBS, pH 7.4, with 0.1% TWEEN 20 and 25 incubated 30 minutes at room temperature prior to use. The plates were then washed 10 times by submersion in PBS, pH 7.4.

Finally, 100 µl/well of o-phenylenediamine dihydrochloride (OPD, Sigma, catalog no. P-3804) was added at 0.5 mg/ml in citrate-phosphate buffer, pH 5.3 with 0.015% H₂O₂ and incubated at room temperature for 15-20 minutes. Then, 100 30 µl/well of 2 N sulfuric acid (VWR, catalog no. VW3500-1) was added and

absorbance read at OD₄₉₀ in a SpectraMax plate reader (Molecular Devices) after agitating the plate for 5 seconds.

Results: The results of the above described experiments are presented in Figures 5, 6, 7 and 8. Specifically, there was a significant increase of OD₄₉₀ in wells incubated with samples reacted with argatroban-C6 NHS ester (compound YL-015-35) as compared to samples containing prequenched argatroban-C6 NHS ester or protein alone. A significant signal above background was detected at approximately 13 ng/ml for HSA-argatroban derivative (see Figure 5) and 12 ng/ml for hGPA-argatroban derivative (5F4 mAb, see Figure 6). The other anti-hGPA monoclonal antibodies (3C10 and 3E4) also detected hGPA-argatroban derivatives, however, at lower levels (see Figures 7 and 8, respectively). These data confirm the thrombin/anti-thrombin results showing that the argatroban-C6 NHS ester has covalently bound to the HSA and hGPA proteins and, once bound, binds to thrombin.

Rabbit erythrocyte ghosts that had been prepared and reacted with 100 μ M argatroban-C6 NHS ester (compound YL-015-35) were also shown to be positive in an plate ELISA format using the polyclonal anti-KLH-argatroban antibodies to detect (rabbit erythrocytes reacted with 50 μ M argatroban-C6 NHS ester were also tested but the signal was much lower). Sham treated rabbit erythrocytes or rabbit erythrocytes treated with the argatroban-C6 free acid (compound YL-015-15) did not give a signal above background. The ELISA assay was similar to the one described above for the HSA and RSA proteins with the exception that either goat anti-rabbit erythrocyte (Cappel, catalog no. 55616) diluted 1:500 or mouse anti-hGPA (BioAtlantic, mAb 3C10) diluted 1:100 in PBS, pH 7.4 were used to capture the argatroban-C6 NHS ester reacted rabbit erythrocyte ghosts. The argatroban-C6 NHS ester was then detected using the polyclonal anti-KLH-argatroban antibodies (1:1000) in the same manner as for the HSA and hGPA proteins above. As a positive control, hGPA labeled with argatroban-C6 NHS ester (same material as above) was included in both assays and detected by the goat anti-rabbit erythrocyte

to 60 ng/ml and the mouse anti-hGPA to 30 ng/ml. Using the goat anti-rabbit erythrocyte to capture, rabbit erythrocyte/NHS-argatroban conjugate was detected to 1.6 - 3.2 μ g/ml of total protein. Using the mouse anti-hGPA (mAb 3C10) to capture, rabbit erythrocyte/NHS-argatroban conjugate was detected at about 160 μ g/ml of total protein.

These results indicate that the argatroban-C6 NHS ester derivative has covalently attached to the rabbit erythrocytes in a manner that is detectable using polyclonal anti-KLH-argatroban antibodies. Since the mouse anti-hGPA was successful with rabbit cells, this assay should also be able to detect argatroban-C6 NHS ester that has covalently attached to human erythrocyte ghosts and whole cells. Moreover, because the goat anti-rabbit erythrocyte antibody was able to detect hGPA, it is likely that this reagent could be used for human erythrocyte ghosts and cells as well.

Example 6: Detection of Thrombin Inhibitory Activity

A variety of assays were employed to detect the ability of argatroban derivatives to inhibit thrombin activity. Specifically, a Km-based chromogenic assay was first employed. Initially, a 1 mL total volume containing argatroban or a derivative thereof, 8 μ M S-2238 (H-D-Phe-Pip-Arg-p-nitroaniline • 2 HCl) as a substrate for thrombin-induced hydrolysis in 0.1% PEG, 1% DMSO in PBS, pH 7.2, 35°C was initiated by the addition of 10 mU of thrombin from human plasma and the absorbance was measured for 10 minutes at 405 nm. Measurements at 405 nm are designed to detect the thrombin-induced liberation of p-nitroaniline from the S-2238 substrate. As such, an observed increase in absorbance at 405 nm directly correlates with an increase in hydrolysis of the substrate by thrombin. The results from these studies indicated that the IC_{50} for underivatized argatroban was 20 nM, whereas the IC_{50} for a C12-tethered carboxylate of argatroban was 150 nM.

Similar results were obtained in a Km-based 96-well formatted fluorogenic assay employing 25 μ M N-t-Boc- β -Benzyl-Asp-Pro-Arg-7-Amido-4-MethylCoumarin HCl as a hydrolysis substrate (total volume 250 μ l, 25 μ M

substrate, in 0.1 mg/ml BSA, PBS in 1% DMSO initiated by addition of 2.5 mU of thrombin from human plasma and absorbance measured for 10 minutes at 460 nm). From these studies, the IC_{50} for underivatized argatroban was 6 nM, for a C12-tethered carboxylate of argatroban, about 80 nM, and for compound YL-015-15, a C6-tethered carboxylate of argatroban, about 50 nM.

In a Vmax-based assay, (total volume 250 μ l, 200 μ M S-2238 as hydrolysis substrate in 0.1% PEG, 1% DMSO in PBS, pH 7.2, 25°C initiated with 40 mU of thrombin from human plasma and measured for 20 minutes at 405 nm) the IC_{50} for underivatized argatroban was 250 nM. The IC_{50} for a C12-tethered carboxylate of argatroban in this assay was about 5-8 μ M. Argatroban derivatized with a C6 instead of a C12-tether had an IC_{50} of 1.25 to 10 μ M, depending on whether in free acid or methyl ester form.

Reaction conditions for conjugation of HSA with an NHS ester derivative of argatroban: 5 μ M HSA was incubated with 235 μ M of NHS ester of argatroban in 1.5 DMSO, 1.5% ethanol in PBS, pH 7.4 for 1.5 hours at room temperature. At this point, the unreacted ester in the sample was quenched by addition of 1.2 mM hydroxylamine and held at room temperature for 30 minutes. Conjugated HSA was desalted on a kwiksep column to remove any unbound forms of the argatroban derivative and concentrated using a centricon-10 column to approximately the initial reaction volume. Appropriate analogous procedures were followed for controls using 1) underivatized HSA protein and 2) HSA protein processed with prequenched argatroban NHS ester.

In a Km-based inhibition assay for thrombin from human plasma, 2.5 mU of thrombin in 10 μ l of 0.1% polyethylene glycol 8000 (PEG) in PBS, pH 7.2, were added to 240 μ l of PBS containing as final concentrations 10 μ M S-2238 hydrolysis substrate, 1% DMSO, 0.1% PEG, and with or without 40 μ g/ml HSA. HSA proteins tested included HSA conjugated with an NHS ester of argatroban, HSA processed with hydroxylamine prequenched NHS ester of argatroban and HSA processed through the same incubations and desaltings used to remove residual or free acid forms of the NHS ester of argatroban as in the above samples. The rate of

substrate hydrolysis by thrombin was nearly linear for the first ten minutes in all cases, as measured by an increase in absorbance at 405 nm from the production of free p-nitroaniline. In duplicate wells 1) lacking HSA or 2) containing underivatized HSA or 3) containing HSA processed with quenched NHS ester of argatroban, the rate of hydrolysis of substrate was indistinguishable between samples and ranged from 0.94 to 1.08 mOD/minute. In duplicate wells containing HSA conjugated with the NHS ester of argatroban, the rate of hydrolysis of substrate ranged from 0.66 to 0.71 mOD/minute, thus, 32% inhibited compared to controls.

In a second independent experiment, HSA was again conjugated with argatroban-C12 NHS ester (compound YL-015-11). Controls containing HSA with prequenched NHS ester, or HSA alone, were also prepared. Samples were assayed in duplicate, and a concentration range of HSA of 20, 40, and 80 mg/ml tested. HSA conjugated with argatroban-C12 NHS ester inhibited thrombin activity from 35-42% at 80 mg/ml compared to control samples, with 15-20% inhibition at 40 mg/ml relative to control samples.

Example 7: K_m -Based Fluorogenic Assay for Inhibition of Thrombin from Human Plasma

Thrombin from human plasma was obtained from Enzyme System Products, Dublin, California, in glycerol:water 1:1, 11.4 mg/ml, 3800 U/mg, MW 36,700, and stored undiluted at -20°C. It was freshly diluted the day of use.

To dilute for the assay, 0.67 μ l (25 Units) of thrombin was pipetted into 5 ml of 0.1 mg/ml BSA (from Pierce, Catalog No. 23209, BSA fraction V, a 2 mg/ml stock in saline with sodium azide), in cold PBS (GIBCO, Catalog No. 14190-136, without calcium chloride and magnesium chloride, pH 7.2) and briefly vortexed, yielding a stock of 5 mU thrombin/ μ l. A second dilution of 250 μ l of this stock into 9.75 ml of 0.1 mg BSA/ml PBS resulted in a 0.125 mU/ μ l, or 3.125 mU/25 μ l, final working stock.

The substrate was N-tBOC- β -Benzyl-Asp-Pro-Arg-7-Amido-4-Methylcoumarin HCl and was obtained from Sigma, Catalog No. B-4028, Lot

122H0070, F.W. 770.3. Five mg was dissolved in 1.42 ml DMSO for a 4 mM stock. The stock was stored in 200 μ l aliquots at -20°C in the dark.

An alternative substrate was N-tBOC-Val-Pro-Arg-7-Amido-4-Methylcoumarin HCl and was obtained from Sigma, Catalog No. B-9385, Lot 53H0805, F.W. of free base 627.7. Five mg was dissolved in 1.863 ml DMSO for a 4 mM stock. The stock was stored in 200 μ l aliquots at -20°C in the dark.

The fluorescent standard was 7-Amido-4-Methylcoumarin and was obtained from Aldrich, Catalog No. 25,737-0, MW 175.19. 6.1 mg was dissolved in 1.743 ml of DMSO for a 20 mM stock. The stock was stored in 200 μ l aliquots at -20°C in the dark.

Assays were performed kinetically at ambient temperature (about 20°C) in 96-well microtiter plates (Nunc Immunomodule Maxisorb, a flat bottomed polystyrene plate) on a Perseptive Biosystems Cytofluor I. Stock solutions containing common concentrations and components for each well or group of well were prepared and 200 μ l aliquotted per microtiter well. Assays were routinely conducted in a total volume of 250 μ l, which allows for 25 μ l for inhibitor and 25 μ l for thrombin (about 3 mU).

For an initial determination of K_m and V_{max} , the concentration of the fluorogenic substrate N-tBOC- β -Benzyl-Asp-Pro-Arg-7-Amido-4-Methylcoumarin was varied from 5 to 200 μ M.

For inhibition assays, final concentrations per well (250 μ l V_T) included 25 μ M N-tBOC- β -Benzyl-Asp-Pro-Arg-7-Amido-4-Methylcoumarin HCl (approximately K_m), 0.1 mg BSA/ml PBS, and 1% DMSO. Initial readings were taken to ensure exclusion of rogue wells with abnormally high backgrounds (λ excitation at 360 nM, bandwidth 40 nM, λ emission, 460 nm, bandwidth 40 nm). Then, 25 μ l of a 10X stock of the putative inhibitor were added per well, mixed for 5 seconds and read kinetically for 10 minutes at ambient temperature to assess background interference and/or any increase in hydrolysis of substrate due to inhibitor.

In inhibition assays using argatroban or soluble, tethered variants of argatroban (C6 or C12), samples were dissolved in DMSO at 1 mM, then diluted appropriately for assay in 1% DMSO in the buffer specified above.

Derivatized argatroban molecules attached to RSA or ghosts derived from red blood cells by an activator were formulated in phosphate buffer. Additional RSA of ghost samples processed (1) with tethered argatroban molecules lacking activator or (2) with activator groups attached to ligands that do not inhibit thrombin were included as negative controls.

The thrombin assay was then initiated by adding 25 μ l of thrombin/well with a multichannel pipettor and mixed for 5 seconds. The appearance of the fluorescent product (free 7-amido-4-methylcoumarin released from the peptide by thrombin) was followed simultaneously in 48 wells (one reading per minute for 30 minutes, λ excitation at 360 nm, bandwidth 40 nm, λ emission, 460 nm, bandwidth 40 nm). The velocity of the reaction was determined as an initial velocity in the first 10 minutes, with the signal in relative fluorescent units (RFU) of an uninhibited reaction about 9,000-10,000, above an initial background reading of about 1,000 (gain setting of 80). Routinely, less than 5% of the initial substrate was converted to fluorescent product during 10 minutes, and samples and curves are run in duplicate. A standard curve of thrombin activity from 0.3125-3.5 mU/well was included, as well as a standard curve of 7-amido-4-methylcoumarin (ranging from 5 to 200 pmoles/well in 1% DMSO, 0.1 mg BSA/ml PBS, V_T 250 μ l/well). The pH of each sample was verified as 7.2 with pH paper at the end of the assay.

The results of the above assays are shown in Figures 9 and 10. Specifically, Figure 9 illustrates the ability of the RSA-argatroban (C6) conjugate to inhibit thrombin. The IC_{50} for this conjugate was estimated to be 25 nM. By contrast, the control RSA sample was not inhibitory at any concentration assayed. This result confirms that the C6-tethered argatroban molecules which are covalently-linked to the RSA protein are bioactive as well as bioavailable. Indeed, this observation was extended to erythrocyte ghosts which were labeled with the C6-tethered argatroban molecule (see Figure 10). This graph illustrates a kinetic assay of increasing

aliquots of ghosts derived from erythrocytes labeled with 100 μ M argatroban (C6)-NHS ester. Control sham-treated ghosts or ghosts derived from cells treated with the corresponding argatroban C6-carboxylate were not inhibitory (data not shown). Taken together, these data demonstrate that carrier proteins, either cellularly- or
5 non-cellularly-associated, when conjugated to tethered argatroban molecules are effective drug carriers and that this treatment maintains the bioactivity of the thrombin inhibitor.

Example 8: Platelet Aggregation Assays

A thrombin-induced platelet aggregation assay was selected to further
10 confirm the bioactivity of the tethered argatroban (C6)-RSA conjugates. The conjugate was prepared according to the following protocol. A 15 μ M solution of RSA in PBS was reacted with 200 μ M argatroban-C6 NHS ester for 1 hour at room temperature. Sham samples consist of the RSA incubated for the same length of time at RT in 2% DMSO in PBS. Each of the samples was then concentrated to a
15 final volume of 1.5 mL using Amicon Centricon 30 filtration/concentration devices. The concentrated samples were then desalted on Pierce's 5 mL Kwiksep cellulose plastic desalting columns. The excluded volumes containing RSA or argatroban-C6-RSA were then subjected to BCA microprotein estimation and lyophilization. In addition, these samples were analyzed by LC/MS, sandwich ELISA assays
20 (described above) to measure thrombin binding and immunoblotting. From LC/MS analysis, an average of 10 tethered argatroban molecules were conjugated to each RSA molecule.

Platelets were purified from freshly drawn human blood diluted with the anticoagulant buffer ACD (9 mls of blood to 1 mL of buffer). The blood was
25 centrifuged for 25 min at 200 x g. The platelet-rich plasma (PRP) was recovered with a plastic pipette. The PRP was centrifuged for 15 min at 3,000 x g in v-shaped plastic tubes. The supernatant, called platelet-poor plasma (PPP), was then removed and saved, and the platelets were resuspended in buffer A1 (35 mM citric acid, 103 mM NaCl, 5 mM each of glucose and KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , 3.5 mg/mL

BSA, 0.1 μM PGE1 and 0.3 U/mL of apyrase at pH 6.5). The resuspended platelets were washed 2 times with buffer A1. After the last wash, the platelets were resuspended in buffer B1 (137 mM NaCl, 2.6 mM KCl, 12 mM NaHCO_3 , 0.3 mM NaH_2PO_4 , 3 mM CaCl_2 , 1 mM MgCl_2 , 5 mM glucose, 3.5 mg/mL BSA and 0.05 U/mL apyrase at pH 7.4) at a density of $3 \times 10^5/\mu\text{L}$. The platelets were maintained at room temperature until ready for use.

Various parameters relevant to platelet aggregation were obtained on a four channel aggregometer manufactured by AFFI BIO. In brief, the reaction chambers are warmed to 37°C and are agitated at a rate of 1,200 rpm. Light is passed through the reaction chambers, with 300 μL of buffer B1 used to set the 100% transmittance level for each chamber. From a series of standardization experiments, it was determined that 0.5 U/mL of human thrombin (Sigma) is an optimal aggregating concentration of thrombin and is used to set the 0% transmittance for the instrument. Standard conditions for the assay involve incubating 250 μL of the platelet suspension with or without 50 μL of inhibitor diluted in buffer in the reaction chambers for 60 seconds at 37°C . The value of transmittance is now set as 0%. After this measurement, thrombin is added to the reaction chambers (20 μl) and transmittance is measured for the next 6 minutes. Samples were performed in triplicate.

Figure 11 depicts the delay in thrombin-induced platelet aggregation affected by various titrations of RSA. By contrast to the sham-treated RSA, the argatroban-C6-RSA clearly delayed platelet aggregation.

Table 1 tabulates the estimated concentrations of the conjugates which inhibit 50% of the aggregation (IC_{50}).

25

TABLE 1

<u>Compound</u>	<u>IC_{50}</u>
Free argatroban	0.1 - 0.15 μM
RSA-argatroban-C6 conjugate	4.5 - 7.5 μM
RSA sham	> 150 μM

As shown in Table 1, using an average of 10 argatroban/RSA and the known dilution of RSA in the samples, the estimated IC_{50} value for the argatroban-C6-RSA was determined to be in the range of 4.5 to 7.5 μM . By contrast, the sham-treated RSA did not interfere with platelet aggregation even at 150 μM . Higher
5 concentrations were not tested, so the IC_{50} for the sham RSA was not determined. The IC_{50} for argatroban in this assay is approximately 0.1 μM , which is in line with literature values. This value is at least an order of magnitude more effective than the argatroban-C6-RSA conjugate. This trend was expected based on the increased IC_{50} observed for the C6-tethered argatroban carboxylate as compared to argatroban in
10 the earlier-described K_m -based fluorogenic thrombin inhibition assay.


It is evident from the above results that the subject invention provides for greatly improved treatment involving thrombin inhibition. By use of the subject invention, the conjugated thrombin inhibitors maintain for extended periods of time, so that repetitive dosages are not required, compliance by the patient is not required,
15 and protection is ensured. The derivatized thrombin inhibitors of the present invention covalently attach to erythrocytes, plasma proteins and various other vascular components while retaining biological activity and are not immunogenic.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication
20 or patent application was specifically and individually indicated to be incorporated by reference.

The invention now being fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein:

Y is a linking group of from 2-30 atoms; and

- 5 Z is a chemically reactive group capable of reaction with a reactive functionality of a target molecule in an aqueous system to form covalent bonds therewith or an activatable precursor to said chemically reactive group; and wherein said compound possesses thrombin inhibitory activity *in vivo* when bonded to a long lived blood component.

- 10 2. The compound according to Claim 1 wherein Y is an alkylene, oxyalkylene or polyoxyalkylene group.


3. The compound according to Claim 1 wherein Y is an alkyl group.

4. The compound according to Claim 3 wherein said alkyl group has 6 carbon atoms.

- 15 5. The compound according to Claim 3 wherein said alkyl group has 12 carbon atoms.

6. The compound according to Claim 1 wherein Z is a carboxy group, a carboxy ester group or a mixed anhydride.
7. The compound according to Claim 6 wherein Z is selected from the group consisting of N-hydroxysuccinimide, isocyanate, thiolester, thionocarboxylic acid ester, imino ester, carbodiimide anhydride, carbonate ester and phosphoryl ester.
8. The compound according to Claim 1 wherein Z is N-hydroxysuccinimide.
9. A composition comprising the compound of Claim 1 and a physiologically acceptable carrier.
10. A method for inhibiting thrombin activity *in vivo*, said method comprising:
 - introducing into the bloodstream of a mammalian host a compound according to Claim 1 in an amount sufficient to provide an effective amount for thrombin inhibition;
 - wherein said compound reacts with and becomes covalently bound to long lived blood components and thrombin inhibition is maintained over an extended period of time as compared to the lifetime of unbound thrombin inhibitor.
11. A method according to Claim 10 wherein said introducing is intravascularly.
12. A method for inhibiting thrombin activity *in vivo*, said method comprising:
 - (a) isolating blood or blood components from a mammalian host;

- (b) contacting *ex vivo* said blood or blood components with a compound according to Claim 1, wherein said compound covalently bonds to one or more reactive functionalities present in said blood or blood components; and
- (c) introducing into the bloodstream of said mammalian host the
- 5 covalently bound blood or blood components obtained in step (b);
- wherein thrombin inhibition is maintained over an extended period of time as compared to the lifetime of unbound thrombin inhibitor.
13. A method according to Claims 10 or 12, including the additional steps of:
- 10 removing a blood sample from said mammalian host; and
- analyzing for the presence of said compound bound to long lived blood components.
14. A blood portion comprising a compound according to Claim 1 covalently bound to at least one long lived blood component.
- 15 15. A blood portion according to Claim 14, wherein said long lived blood component is immunoglobulin.
16. A blood portion according to Claim 14, wherein said long lived blood component is erythrocytes.
17. A conjugate comprising a compound according to Claim 1 covalently
- 20 bound to a blood component selected from the group consisting of serum albumin, immunoglobulin and erythrocytes.
18. The conjugate according to Claim 17 wherein said blood component is serum albumin.



2 / 11





FIG. 2

SUBSTITUTE SHEET (RULE 26)

3 / 11

**FIG._3**

4/11




FIG. 4

5 / 11




FIG. 5

6 / 11




FIG._6

7 / 11




FIG. 7

8 / 11






FIG. 8


9 / 11

**FIG. 9**

10 / 11

**FIG. 10**

SUBSTITUTE SHEET (RULE 26)


**FIG. 11**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 47/48		A3	(11) International Publication Number: WO 98/00171
			(43) International Publication Date: 8 January 1998 (08.01.98)
(21) International Application Number: PCT/IB97/01093		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 June 1997 (30.06.97)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 08/674,315 1 July 1996 (01.07.96) US		(88) Date of publication of the international search report: 4 June 1998 (04.06.98)	
(71) Applicant: REDCELL CANADA INC. [CA/CA]; Suite 810, 1801 Boulevard de Maisonneuve Ouest, Montreal, Quebec H3H 1J9 (CA).			
(72) Inventors: KRANTZ, Alexander; Apartment D24, 350 Sharon Park Drive, Menlo Park, CA 94025 (US). EZRIN, Alan, M.; 110 Quintas Lane, Moraga, CA 94556 (US). SONG, Yonghong; Apartment K309, 1125 Balclutha Drive, Foster City, CA 94404 (US).			
(74) Agent: COTE, France; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Quebec H3A 2Y3 (CA).			

(54) Title: CONJUGATES OF THROMBIN INHIBITORS AND ENDOGENES CARRIERS



(57) Abstract

Novel compounds comprising chemically reactive intermediates which can react with available reactive functionalities on blood components to form covalent linkages, where the resulting covalently-bound conjugates are found to have thrombin inhibition activity are provided. Specifically, the thrombin inhibitor compounds of the present invention are derivatives of the known thrombin inhibitor argatroban, which can be covalently linked to chemically reactive functionalities on various blood components. The conjugated thrombin inhibitors thereby have extended lifetimes in the blood stream, as compared to the unconjugated parent drug, and are, therefore, capable of maintaining thrombin inhibitory activity for extended periods of time as compared to the unconjugated parent drug. Also provided herein are methods for inhibiting thrombin activity *in vivo* comprising administering to the bloodstream of a mammalian host the novel compounds of the present invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 97/01093

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	US 5 612 034 A (POULETTY, PHILIPPE ET AL) 18 March 1997 see claims	
P,Y	--- A. KRANTZ: "RED CELL-MEDIATED THERAPY: OPPORTUNITIES AND CHALLENGES." BLOOD CELLS, MOLECULES, AND DISEASES, vol. 23, no. 3, February 1997, pages 58-68, XP002059040	1-18
P,X	see page 58, column 2, paragraph 2; figures 1,2,4	1
Y	--- WO 94 09034 A (AGEN LTD ;EISENBERG PAUL (US); RYLATT DENNIS BRIAN (AU); HILLYARD) 28 April 1994	1-18
X	see page 7, line 8 - line 10; claims 1,7,8,13	1,14,15, 17
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

16 March 1998

Date of mailing of the international search report

24.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 97/01093

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 632 991 A (M.A. GRIMBONE) 27 May 1997 see column 10, line 49 - line 52 see column 10, line 57 - line 8; claims 1,2,11 ---	1,6-12, 14,15,17
A	WO 95 10302 A (REDCELL INC) 20 April 1995 see page 30, line 23 - page 31, line 10; claims 1-4 ---	1,10
Y	EP 0 602 290 A (POULETTY PHILIPPE ;POULETTY CHRISTINE (US)) 22 June 1994 see column 5, line 32 - column 6, line 10; claims 1-3,7,15 ---	1-18
A	US 5 433 940 A (MARAGANORE JOHN M ET AL) 18 July 1995 see column 9, line 30 - line 31; claim 1 ---	1-18
X	DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL AN=87018644, XP002059041 see abstract & WAKAI N. ET AL.: "STUDIES ON ANTIGENICITY OF ARGIPIDINE (MD-805)" JPN. PHARMACOL. THER., vol. 14, no. SUPPL. 5, 1986, pages 197-206, -----	1,6-12, 14,17,18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 97/01093

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/IB 97/01093

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 10-13
are directed to a method of treatment of
the human/animal body , the search has been carried out and based on the
alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 97/01093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5612034 A	18-03-97	AU 7955894 A CA 2172630 A EP 0793506 A JP 9503511 T WO 9510302 A	04-05-95 20-04-95 10-09-97 08-04-97 20-04-95
WO 9409034 A	28-04-94	AU 5145893 A EP 0668875 A ZA 9307553 A	09-05-94 30-08-95 03-05-94
US 5632991 A	27-05-97	US 5403713 A AT 142505 T AU 636589 B AU 4621789 A CA 2002860 A DE 68927188 D DE 68927188 T EP 0534944 A JP 4501565 T WO 9005539 A	04-04-95 15-09-96 06-05-93 12-06-90 14-05-90 17-10-96 24-04-97 07-04-93 19-03-92 31-05-90
WO 9510302 A	20-04-95	US 5612034 A AU 7955894 A CA 2172630 A EP 0793506 A JP 9503511 T	18-03-97 04-05-95 20-04-95 10-09-97 08-04-97
EP 0602290 A	22-06-94	NONE	
US 5433940 A	18-07-95	US 5196404 A US 5691311 A AT 137246 T AU 652125 B AU 6284190 A BG 60759 B CA 2065150 A DE 69026715 D DE 69026715 T EP 0489070 A ES 2086411 T	23-03-93 25-11-97 15-05-96 18-08-94 03-04-91 29-02-96 19-02-91 30-05-96 17-10-96 10-06-92 01-07-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 97/01093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5433940 A		HU 211158 B	30-10-95
		JP 7068141 B	26-07-95
		JP 4507253 T	17-12-92
		MX 9203194 A	01-09-92
		MX 9203196 A	01-09-92
		WO 9102750 A	07-03-91
		US 5514409 A	07-05-96
		US 5240913 A	31-08-93
		US 5425936 A	20-06-95
